Blackhawk Growth Corp. announced that it has entered into a financing agreement (the "Credit Facility") for up to $10-million. The loan facility was arranged by RiverFort Global Capital Ltd. (a United Kingdom London-based firm regulated by the Financial Conduct Authority) ("RiverFort") and funded by a regulated institutional investor (the "Investor"). The Corporation intends to utilize the proceeds from the Credit Facility to support the Corporation's research undertaken in Trip Pharma as well as for operational and working capital purposes of Blackhawk. Pursuant to the terms of the Credit Facility, Blackhawk has agreed to draw down an initial tranche of $2.5-million, with this debt maturing on November 22, 2023, with interest payable by Blackhawk in an amount equal to 10 per cent per annum on the tranche.